tiprankstipranks
Trending News
More News >

Biohaven initiates global Phase 2/3 study of BHV-8000

Biohaven (BHVN) announced that it has initiated a global Phase 2/3 study of the first-in-clinic, orally-administered, brain-penetrant, and highly selective TYK2/JAK1 inhibitor, BHV-8000, for the treatment of early Parkinson’s disease. The trial will enroll 550 patients at approximately 185 sites across 13 countries including the United States, Canada, and 11 European nations.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue